CD274 and neoplasm: reported that anlotinib and anti-PD-1/PD-L1 antibody acted synergistically to provide therapeutic benefit by promoting infiltration of natural killer cells, M1-like tumor-associated macrophages (TAM), and dendritic cells, while reducing the infiltration of M2-like TAM (35).